Clinical implications of T-Cells CX3CR1+, Toll-like Receptor 4 signaling pathway, and immune checkpoints in Non-Muscle Invasive Bladder Cancer
DOI:
https://doi.org/10.34119/bjhrv6n2-307Palabras clave:
Bladder Cancer, Toll-like receptor 4, CX3CR1Resumen
Background: This study characterized and compared the molecular profiles of CX3C chemokine receptor 1 (CX3CR1, a marker of T-cell differentiation), Toll-like receptor 4 (TLR4)-mediated interferon signaling pathway, and immune checkpoints in the different histological stages of non-muscle invasive bladder cancer (NMIBC), aiming the investigation of these biomarkers as a criterion of clinical response to immunotherapy. Methods: Seventy-five formalin-fixed paraffin-embedded samples of bladder were obtained from 34 to 96-year-old patients (mean 65 years) with NMIBC diagnosis in University of Campinas (UNICAMP) and Paulinia Municipal Hospital/ Brazil. Subsequently, the samples were divided into 3 groups (n= 25 samples per group): pTis group, high-grade pTa group, and pT1 group; and submitted to immunohistochemistry analysis: TLR4-mediated IFN-γ production signaling pathway (TRIF, TBK1, IRF-3, IFN-γ), CX3CR1+CD8+ T-cells, immune checkpoints (PD-1/PD-L1 and CTLA-4), and regulatory T (Treg) cells (FOXP3). The retrospective anonymous study was approved by the local ethics committee (Clinical Trial: RBR-6swqd2). Results: pTis group showed the lowest activation of TLR4-mediated IFN-γ signaling pathway when compared (p<0.01) to high-grade pTa and pT1 groups. Both the immunoreaction intensity and positive cells percentage were lower (p<0.01) for TLR4, TRIF, IRF-3, and IFN-γ in the pTis group with respect to other groups. No statistical difference was found between high-grade pTa and pT1 groups for these biomarkers. Likewise, CX3CR1 immunoreactivities were remarkably lower (p<0.01) in the pTis group in comparison with high-grade pTa and pT1 groups, which did not show statistical differences between them. Furthermore, immune checkpoints (PD-1/PD-L1 and CTLA4) and FOXP3+ Treg cells immunoreactivities were significantly higher (p<0.01) in the high-grade pTa and pT1 compared to the pTis group. Conclusions: Our data demonstrated that pTis stage was characterized by an immunosuppressive microenvironment in comparison with pTa and pT1 stages, showing decreased TLR4-mediated interferon signaling pathway and low activation of CX3CR1+CD8+ T-cells; which implies in low sensitivity to immunotherapy. The larger number of FOXP3+ Treg cells in pTa and pT1 was correlated with intensified immune checkpoints immunoreactivities, indicating higher sensitivity to immunotherapy. Finally, these biomarkers may be useful in the clinical management of patients with NMIBC.
Citas
American Cancer Society. Overview: bladder cancer. In: What are the key statistics about bladder cancer? American Cancer Society, Atlanta. Disponível em: https://www.cancer.org/cancer/bladder-cancer.html. Acesso em: 23/03/2022.
Fávaro WJ, Alonso JCC, de Souza BR, et al. New synthetic nano-immunotherapy (OncoTherad®) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property. Tissue Cell. 2023; 80:101988. https://doi.org/10.1016/j.tice.2022.101988
Rubio C, Munera-Maravilla E, Lodewijk I, et al. Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods? Clin Transl Oncol. 2019; 21:391-403. https://doi.org/10.1007/s12094-018-1952-y
Disis ML. Immune regulation of cancer. J Clin Oncol. 2010; 28: 4531. https://doi.org/10.1200/jco.2009.27.2146
Yang Y, Feng R, Wang YZ, et al. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy. Immunol Lett. 2020; 223:1-9. https://doi.org/10.1016/j.imlet.2020.04.002
Bourquin C, Pommier A, Hotz C. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2020; 154:104192. https://doi.org/10.1016/j.phrs.2019.03.001
Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004; 16: 3-9. https://doi.org/10.1016/j.smim.2003.10.003
Satoh T, Akira S. Toll-like receptor signaling and its inducible proteins. Microbiol Spectr. 2016; 4:MCHD-0040-2016. https://doi.org/10.1128/microbiolspec.mchd-0040-2016
Jouhi L, Renkonen S, Atula T, et al. Different Toll-Like Receptor Expression Patterns in Progression toward Cancer. Front Immunol. 2014; 5:638. https://doi.org/10.3389/fimmu.2014.00638
Urban-Wojciuk Z, Khan MM, Oyler BL, et al. The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. Front Immunol. 2019; 10:2388. https://doi.org/10.3389/fimmu.2019.02388
Vinnakota K, Hu F, Ku MC, et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol. 2013; 5:1457-68. https://doi.org/10.1093/neuonc/not115
Jin B, Sun T, Yu XH, et al. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol. 2012; 2012:836485. https://doi.org/10.1155/2012/836485
Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Front Pharmacol. 2018; 9:878. https://doi.org/10.3389/fphar.2018.00878
Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018; 3:214-234. https://doi.org/10.1038/modpathol.2017.156
Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res. 2022; 41:35. https://doi.org/10.1186/s13046-022-02251-2
Yamauchi T, Hoki T, Oba T, et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun. 2021; 12:1402. https://doi.org/10.1038/s41467-021-21619-0
Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs. 2011; 71:1093–104. https://doi.org/10.2165/11594010-000000000-00000
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252–64. https://doi.org/10.1038/nrc3239
Zhang Y, Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol. 2020; 1248:201-226. https://doi.org/10.1007/978-981-15-3266-5_9
Kim JE, Lim M. The role of checkpoints in the treatment of GBM. J Neuro-Oncol. 2015; 123:413–23. https://doi.org/10.1007/s11060-015-1747-8
Barrueto L, Caminero F, Cash L, et al. Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol. 2020; 13:100738. https://doi.org/10.1016/j.tranon.2019.12.010
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711–23. https://doi.org/10.1056/nejmoa1003466
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366:2455–65. https://doi.org/10.1056/nejmoa1200694
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with Lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013; 369:134–44. https://doi.org/10.1056/nejmoa1305133
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39:98–106. https://doi.org/10.1097/coc.0000000000000239
Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder. Am J Surg Pathol. 1998; 22:1435-1448. https://doi.org/10.1097/00000478-199812000-00001
Reis IB, Tibo LHS, de Souza BR, et al. OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol. 2022; Nov 2. https://doi.org/10.1007/s00432-022-04449-5
Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 2004; 6:297-305. https://doi.org/10.1016/j.ccr.2004.08.012
Shankaran V, Iked H, Bruce AT, et al. IFN gamma and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature 2001; 410:1107–11. https://doi.org/10.1038/35074122
Alshaker HA, Matalka KZ. IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011; 11:33. https://doi.org/10.1186/1475-2867-11-33
Tate Jr DJ, Patterson JR, Velasco-Gonzalez C, et al. Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci. 2012; 8:1109-1120. https://doi.org/10.7150/ijbs.4694
Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leun MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014; 41:830-42. https://doi.org/10.1016/j.immuni.2014.10.017
Lu JL, Xia QD, Sun Y, et al. Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis. Front Cell Dev Biol. 2021; 9:651560. https://doi.org/10.3389/fcell.2021.651560
Ohadian Moghadam S, Nowroozi MR. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol. 2019; 90:e12818. https://doi.org/10.1111/sji.12818
Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol. 2013; 6:1041-1053. https://doi.org/10.1038/mi.2013.72
Loskog A, Ninalga C, Paul-Wetterberg G, et al. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007; 177:353- 358. https://doi.org/10.1016/j.juro.2006.08.078
Smith SG, Zaharoff DA. Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy. 2016; 8:351-365. https://doi.org/10.2217/imt.15.122
